贝瑞基因: 关于持股5%以上股东所持部分股份被司法强制执行实施结果的公告

Group 1 - The controlling shareholder, Mr. Gao Yang, has faced forced execution of up to 3,535,214 shares of the company, representing no more than 1% of the total share capital, due to a default in a stock pledge repurchase business [1][2] - The forced execution period is from May 20, 2025, to June 9, 2025, with an execution average price of 13.10 yuan per share [2][3] - Prior to the forced execution, Mr. Gao held 31,988,723 shares (9.0486% of total share capital), which decreased to 28,453,510 shares (8.0486%) after the execution [3] Group 2 - The shares being executed were obtained through a major asset restructuring transaction involving the acquisition of 100% equity of Beijing Berry and Kang Biotechnology Co., Ltd. [2] - The forced execution does not violate any previously disclosed holding intentions or commitments by the controlling shareholder [3][4] - The combined shareholding of Mr. Gao and his concerted action partner, Ms. Hou Ying, decreased from 14.27% to 11.95% during the execution period [3]